STOCK TITAN

Lineage Cell Therapeutics: Broadwood buys 1M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Broadwood Partners, L.P. purchased 1,000,000 Lineage Cell Therapeutics common shares at $0.7707 per share on November 17, 2026. The shares are directly owned by Broadwood Partners. Broadwood Capital, Inc., its general partner, and Neal C. Bradsher, Broadwood Capital’s president, may be deemed beneficial owners; each disclaims beneficial ownership except to the extent of a pecuniary interest. No Rule 10b5-1 plan is reported.

The report lists directly held Common Warrants exercisable for 7,894,737 common shares at $0.91 per share. They are currently exercisable and expire on the earlier of May 21, 2028, or the 90th day following public disclosure of intent to advance OpRegen (RG6501) into a multi-center phase 2 or 3 clinical trial with a control or comparator arm. If that disclosure occurs before May 21, 2025, the stated expiration is the 90th day following May 21, 2025.

Insider BROADWOOD PARTNERS, L.P., BROADWOOD CAPITAL INC, Bradsher Neal C
Role Director, 10% Owner | 10% Owner | Director, 10% Owner
Bought 1,000,000 shs ($771K)
Type Security Shares Price Value
Purchase Common Shares F1 1,000,000 $0.7707 $771K
Purchase Common Shares F1 0 $0.00 $0.00
Holding Common Warrant F3, F4, F1 -- -- --
Holding Common Warrant F3, F4, F1 -- -- --
Holding Common Shares F2 -- -- --
Holdings After Transaction: Common Shares — 50,648,620 shares (Direct); Common Shares — 50,560,992 shares (Indirect, See Footnote); Common Warrant — 7,894,737 warrants (Direct); Common Warrant — 7,894,737 warrants (Indirect, See Footnote)
Footnotes (4)
  1. F1. The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  2. F2. These securities are owned by Neal C. Bradsher in his personal capacity.
  3. F3. These common share purchase warrants (the "Common Warrants") are currently exercisable.
  4. F4. The Common Warrants will expire on the earlier of (a) May 21, 2028 and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to May 21, 2025, then the 90th day following May 21, 2025.
Common shares purchased 1,000,000 shares Broadwood Partners purchase on November 17, 2026
Purchase price $0.7707 per share Broadwood Partners purchase on November 17, 2026
Reported indirect shares following transaction 50,560,992 shares The transaction row reports no shares acquired in this indirect entry; related reporting persons may be deemed beneficial owners and disclaim beneficial ownership except to the extent of a pecuniary interest.
Common Warrant underlying shares 7,894,737 shares Reported directly held warrants; currently exercisable
Common Warrant exercise price $0.91 per share Reported directly held warrants
Common Warrant expiration May 21, 2028, or earlier under the stated disclosure condition Expiration is the earlier of this date or the 90th day following the specified OpRegen trial disclosure, subject to the stated pre-May 21, 2025 clause.
Common Warrants technical
"The Common Warrants are currently exercisable."
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
beneficially owned regulatory
"may be deemed beneficially owned by Broadwood Capital, Inc."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
pecuniary interest financial
"except to the extent of his or its pecuniary interest therein"
General Partner technical
"as General Partner of Broadwood Partners"
A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.
multi-center phase 2 or 3 clinical trial medical
"into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LCTX shares did Broadwood Partners buy?

Broadwood Partners, L.P. purchased 1,000,000 common shares at $0.7707 per share on November 17, 2026. No Rule 10b5-1 plan is reported.

When do the reported LCTX warrants expire?

They expire on the earlier of May 21, 2028, or the 90th day following the specified OpRegen trial disclosure. The disclosure must state an intent to advance OpRegen (RG6501) into a multi-center phase 2 or 3 clinical trial that includes a control or comparator arm. If that disclosure occurs before May 21, 2025, the stated expiration is the 90th day following May 21, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BROADWOOD PARTNERS, L.P.

(Last)(First)(Middle)
C/O BROADWOOD CAPITAL INC.
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [ LCTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares11/17/2026P1,000,000A$0.770750,560,992D(1)
Common Shares11/17/2026P0A$050,560,992ISee Footnote(1)
Common Shares87,628D(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Common Warrant$0.91 (3) (4)Common Shares7,894,7377,894,737D(1)
Common Warrant$0.91 (3) (4)Common Shares$7,894,7377,894,737ISee Footnote(1)
1. Name and Address of Reporting Person*
BROADWOOD PARTNERS, L.P.

(Last)(First)(Middle)
C/O BROADWOOD CAPITAL INC.
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
BROADWOOD CAPITAL INC

(Last)(First)(Middle)
156 WEST 56TH STREET
3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Bradsher Neal C

(Last)(First)(Middle)
C/O BROADWOOD CAPITAL INC.
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
2. These securities are owned by Neal C. Bradsher in his personal capacity.
3. These common share purchase warrants (the "Common Warrants") are currently exercisable.
4. The Common Warrants will expire on the earlier of (a) May 21, 2028 and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to May 21, 2025, then the 90th day following May 21, 2025.
Broadwood Partners, L.P., By: Broadwood Capital, Inc., /s/ Neal C. Bradsher, President11/19/2026
By: Broadwood Capital, Inc., /s/ Neal C. Bradsher, President11/19/2026
/s/ Neal C. Bradsher11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading